RxDoctor Payments Data

Aaron Best, DO

Internal Medicine · Media, PANPI 1518141860

Payments from drug & device makers

$6,887in general payments, 2019–2025

Across 417 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$951
  • Pfizer$534
  • Boehringer Ingelheim$347
  • Lilly USA, LLC$327
  • Merck$323
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,873100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,887 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$63,694
Medicare patients
417
Services billed
763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$40,518
EliquisApixaban49$34,959
TrulicityDulaglutide31$34,926
JardianceEmpagliflozin31$34,114
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$31,071
RybelsusSemaglutide20$27,005
Xtampza ErOxycodone Myristate22$26,313
FarxigaDapagliflozin Propanediol18$21,986
MounjaroTirzepatide11$12,669
XareltoRivaroxaban14$11,699
Breo ElliptaFluticasone/Vilanterol12$7,204
LinzessLinaclotide11$6,491
Atorvastatin Calcium385$3,994
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$3,917
Rosuvastatin Calcium124$3,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,320$67,52263 claims
Lilly USA, LLCTrulicity, Mounjaro$327$47,59442 claims
GSKTrelegy Ellipta, Breo Ellipta$143$38,27549 claims
PfizerEliquis, Paxlovid$534$36,38865 claims
Boehringer IngelheimJardiance$347$34,11431 claims
Collegium Pharmaceutical, Inc.Xtampza Er$212$26,31322 claims
AstraZenecaFarxiga$294$21,98618 claims
Johnson & JohnsonXarelto$309$11,69914 claims
AbbVieLinzess, Synthroid$951$8,21436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Media

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →